Hangzhou-based Medim Science, China’s first pharma firm focused on macrophage-targeting biologics, has reportedly raised tens of millions of renminbi in a new financing round led by Ming Bioventures, with Cowin Venture Capital participating. The funds will support R&D, regulatory filings, and clinical trial applications for its pipeline targeting solid tumors.
Funding Details
The proceeds will drive development of Medim’s macrophage-focused therapies, which aim to enhance tumor cell phagocytosis, activate T cells, and reprogram the tumor immune microenvironment. The company plans to file for clinical trials and regulatory approvals to advance its pipeline.
Drug Mechanism
Medim’s biologics leverage macrophages to improve immune responses against cancer. By boosting phagocytosis and downstream T-cell activation, the drugs seek to treat or potentially cure solid tumors, addressing a major gap in oncology care.
Strategic Outlook
The funding positions Medim to accelerate clinical trials and establish its macrophage-targeting platform as a novel approach in cancer immunotherapy. With growing interest in macrophage-based treatments, the company aims to lead China’s innovation in this space.-Fineline Info & Tech
